意大利肝脏研究协会关于 SARS-CoV2 疫苗接种的立场声明。
Italian association for the study of the liver position statement on SARS-CoV2 vaccination.
机构信息
Department of Surgery, University Hospital Padua, Oncology and Gastroenterology, Italy.
Department of Medicine, University Hospital Padua, Italy.
出版信息
Dig Liver Dis. 2021 Jun;53(6):677-681. doi: 10.1016/j.dld.2021.03.013. Epub 2021 Apr 30.
Abstract
The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.
摘要
意大利于 2020 年 12 月底启动了针对 SARS-CoV-2 的疫苗接种运动。第一批接种该病毒疫苗的是卫生工作者和养老院的居民，之后疫苗将提供给全体人群，首先是最脆弱的人群。目前已证明 SARS-CoV2 疫苗对普通人群是安全的，尽管到目前为止尚无针对肝病患者或接受过肝移植的患者的相关数据。本 AISF 立场声明试图根据发表的关于慢性肝病患者 SARS-CoV-2 感染影响的数据，为这一类别患者的疫苗接种提出一个可能的优先顺序。
相似文献
1
Italian association for the study of the liver position statement on SARS-CoV2 vaccination.
Dig Liver Dis. 2021 Jun;53(6):677-681. doi: 10.1016/j.dld.2021.03.013. Epub 2021 Apr 30.
2
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6.
3
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
J Hepatol. 2021 Dec;75(6):1434-1439. doi: 10.1016/j.jhep.2021.08.008. Epub 2021 Aug 26.
4
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
5
Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
Environ Health Prev Med. 2021 Sep 30;26(1):99. doi: 10.1186/s12199-021-01018-z.
6
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
Viruses. 2022 Aug 12;14(8):1766. doi: 10.3390/v14081766.
7
Can COVID-19 vaccines stop the pandemic?
Hong Kong Med J. 2021 Apr;27(2):84-85. doi: 10.12809/hkmj215116.
8
Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.
Saudi J Gastroenterol. 2021 Jul-Aug;27(4):201-207. doi: 10.4103/sjg.sjg_223_21.
9
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158. doi: 10.1016/S2468-1253(21)00008-X. Epub 2021 Jan 11.
10
SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients.
Clin Transplant. 2024 Jul;38(7):e15407. doi: 10.1111/ctr.15407.
引用本文的文献
1
COVID-19 Vaccine Perception in Liver Transplant Recipients: Patient-Reported Outcomes and Real-Life Experience from the Bergamo Center.
Vaccines (Basel). 2025 Apr 24;13(5):455. doi: 10.3390/vaccines13050455.
2
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors.
Vaccines (Basel). 2025 Mar 26;13(4):352. doi: 10.3390/vaccines13040352.
3
Approaches for Selective Vaccinations in Cirrhotic Patients.
Vaccines (Basel). 2023 Feb 16;11(2):460. doi: 10.3390/vaccines11020460.
4
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination.
World J Gastroenterol. 2023 Feb 7;29(5):800-814. doi: 10.3748/wjg.v29.i5.800.
5
Investigation on the hesitancy of COVID-19 vaccination among liver transplant recipients: A cross-sectional study in China.
Front Public Health. 2022 Dec 15;10:1014942. doi: 10.3389/fpubh.2022.1014942. eCollection 2022.
6
Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.
Front Med (Lausanne). 2022 Jun 22;9:924454. doi: 10.3389/fmed.2022.924454. eCollection 2022.
7
Sars-Cov-2 vaccination in liver transplant recipients: The 'holy grail' in a hostile environment.
Liver Int. 2022 Jun;42(6):1225-1228. doi: 10.1111/liv.15226.
8
Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
J Hepatol. 2022 Jul;77(1):152-162. doi: 10.1016/j.jhep.2022.02.015. Epub 2022 Mar 10.
9
Management of COVID-19 patients with chronic liver diseases and liver transplants.
Ann Hepatol. 2022 Jan-Feb;27(1):100653. doi: 10.1016/j.aohep.2021.100653. Epub 2021 Dec 18.
10
COVID-19 Vaccine Acceptance among Liver Transplant Recipients.
Vaccines (Basel). 2021 Nov 11;9(11):1314. doi: 10.3390/vaccines9111314.
本文引用的文献
1
A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection.
Transpl Int. 2021 Apr;34(4):756-757. doi: 10.1111/tri.13842. Epub 2021 Feb 27.
2
Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection.
Liver Int. 2021 Aug;41(8):1824-1831. doi: 10.1111/liv.14804. Epub 2021 Feb 16.
3
SARS-CoV-2 infection in patients with autoimmune hepatitis.
J Hepatol. 2021 Jun;74(6):1335-1343. doi: 10.1016/j.jhep.2021.01.021. Epub 2021 Jan 26.
4
Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.
Nat Rev Endocrinol. 2021 Mar;17(3):135-149. doi: 10.1038/s41574-020-00462-1. Epub 2021 Jan 21.
5
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158. doi: 10.1016/S2468-1253(21)00008-X. Epub 2021 Jan 11.
6
The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine-United States, 2020.
Am J Transplant. 2021 Jan;21(1):420-425. doi: 10.1111/ajt.16437.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study.
Liver Int. 2021 Apr;41(4):720-730. doi: 10.1111/liv.14774. Epub 2021 Jan 10.
9
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
10
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.
J Hepatol. 2021 Mar;74(3):670-685. doi: 10.1016/j.jhep.2020.11.048. Epub 2020 Dec 7.
Zotero 插件